IDP-001

InduPro Therapeutics has struck its second major pharma deal in a month, announcing a partnership with Eli Lilly valued at up to $950 million. The agreement, which also includes an equity investment, follows InduPro's tie-up with Sanofi in December to advance a bispecific PD-1 agonist for autoimmune diseases.Under the terms of the Lilly agreement, the companies will explore up to three targets using InduPro's proximity-guided approach, which identifies so-called tumour-associated proximity antigens (TAPAs) – surface proteins that are spatially co-localised and often functionally linked with tumour-associated antigens (TAAs) – to allow for selective co-targeting in bispecific and multispecific therapies."TAPAs represent a fundamentally new way to think about tumour antigens," said CEO Prakash Raman. "We believe this partnership reflects growing confidence in our differentiated, proximity-guided approach to tumour targeting and its promise to improve the design and performance" of antibody-drug conjugates (ADCs) and T-cell engagers.The deal gives Lilly access to InduPro's AI/ML-enabled membrane interactomics (MInt) platform, while InduPro will lead early discovery and co-target identification. Lilly will also make an equity investment in InduPro.InduPro's most advanced oncology asset is IDP-001, a first-in-class proximity-based bispecific ADC designed to target both EGFR and a novel TAA. An IND filing is planned for the first quarter of 2026. It has two other assets, IDP-004 and IDP-005, in the discovery stage.